Johnson & Johnson Gross Profit 2010-2024 | JNJ
Johnson & Johnson annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Johnson & Johnson gross profit for the quarter ending September 30, 2024 was $15.508B, a 5.17% increase year-over-year.
- Johnson & Johnson gross profit for the twelve months ending September 30, 2024 was $60.555B, a 12.87% increase year-over-year.
- Johnson & Johnson annual gross profit for 2023 was $58.606B, a 5.8% increase from 2022.
- Johnson & Johnson annual gross profit for 2022 was $55.394B, a 0.1% increase from 2021.
- Johnson & Johnson annual gross profit for 2021 was $55.338B, a 2.18% increase from 2020.
Johnson & Johnson Annual Gross Profit
(Millions of US $) |
| 2023 |
$58,606 |
| 2022 |
$55,394 |
| 2021 |
$55,338 |
| 2020 |
$54,157 |
| 2019 |
$54,503 |
| 2018 |
$54,490 |
| 2017 |
$51,011 |
| 2016 |
$50,101 |
| 2015 |
$48,538 |
| 2014 |
$51,585 |
| 2013 |
$48,970 |
| 2012 |
$45,566 |
| 2011 |
$44,670 |
| 2010 |
$42,795 |
| 2009 |
$43,450 |
Johnson & Johnson Quarterly Gross Profit
(Millions of US $) |
| 2024-09-30 |
$15,508 |
| 2024-06-30 |
$15,578 |
| 2024-03-31 |
$14,872 |
| 2023-12-31 |
$14,597 |
| 2023-09-30 |
$14,745 |
| 2023-06-30 |
$15,057 |
| 2023-03-31 |
$14,207 |
| 2022-12-31 |
$9,641 |
| 2022-09-30 |
$13,824 |
| 2022-06-30 |
$16,101 |
| 2022-03-31 |
$15,828 |
| 2021-12-31 |
$8,267 |
| 2021-09-30 |
$16,088 |
| 2021-06-30 |
$15,725 |
| 2021-03-31 |
$15,258 |
| 2020-12-31 |
$14,661 |
| 2020-09-30 |
$14,110 |
| 2020-06-30 |
$11,757 |
| 2020-03-31 |
$13,629 |
| 2019-12-31 |
$13,613 |
| 2019-09-30 |
$13,862 |
| 2019-06-30 |
$13,622 |
| 2019-03-31 |
$13,406 |
| 2018-12-31 |
$13,433 |
| 2018-09-30 |
$13,759 |
| 2018-06-30 |
$13,903 |
| 2018-03-31 |
$13,395 |
| 2017-12-31 |
$12,936 |
| 2017-09-30 |
$12,725 |
| 2017-06-30 |
$12,993 |
| 2017-03-31 |
$12,357 |
| 2016-12-31 |
$12,468 |
| 2016-09-30 |
$12,334 |
| 2016-06-30 |
$13,146 |
| 2016-03-31 |
$12,153 |
| 2015-12-31 |
$12,138 |
| 2015-09-30 |
$11,878 |
| 2015-06-30 |
$12,430 |
| 2015-03-31 |
$12,092 |
| 2014-12-31 |
$12,401 |
| 2014-09-30 |
$13,068 |
| 2014-06-30 |
$13,456 |
| 2014-03-31 |
$12,660 |
| 2013-12-31 |
$12,400 |
| 2013-09-30 |
$12,231 |
| 2013-06-30 |
$12,388 |
| 2013-03-31 |
$11,951 |
| 2012-12-31 |
$11,555 |
| 2012-09-30 |
$11,455 |
| 2012-06-30 |
$11,332 |
| 2012-03-31 |
$11,224 |
| 2011-12-31 |
$10,917 |
| 2011-09-30 |
$10,933 |
| 2011-06-30 |
$11,425 |
| 2011-03-31 |
$11,395 |
| 2010-12-31 |
$10,604 |
| 2010-09-30 |
$10,388 |
| 2010-06-30 |
$10,700 |
| 2010-03-31 |
$11,103 |
| 2009-12-31 |
$11,239 |
| 2009-09-30 |
$10,647 |
| 2009-06-30 |
$10,789 |
| 2009-03-31 |
$10,775 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$347.829B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
